We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $10.1B
1-Year Est. Return 42.88%
This Fund
S&P 500
This Quarter Est. Return
+3.5%
1 Year Est. Return
+42.88%
3 Year Est. Return
+92.52%
5 Year Est. Return
+113.84%
10 Year Est. Return
+608.05%
AUM
$10.8B
AUM Growth
-$222M
Cap. Flow
-$287M
Cap. Flow %
-2.66%
Top 10 Hldgs %
9.23%
Holding
920
New
57
Increased
332
Reduced
337
Closed
91

Top Buys

Rank Stock Value
1
LCII icon
LCI Industries
LCII
+$19.9M
2
KWR icon
Quaker Houghton
KWR
+$19.1M
3
FORM icon
FormFactor
FORM
+$17.5M
4
AMSF icon
AMERISAFE
AMSF
+$16.5M
5
TKR icon
Timken Company
TKR
+$16.3M

Sector Composition

Rank Sector Weight
1 Industrials 25.23%
2 Technology 19.83%
3 Financials 14.91%
4 Consumer Discretionary 12.13%
5 Healthcare 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KFRC icon
551
Kforce
KFRC
$1.02B
$3.33M 0.03%
58,728
-122
-0.2% -$7.09K
MXCT icon
552
MaxCyte
MXCT
$112M
$3.33M 0.03%
799,873
+475,949
+147% +$1.8M
IRWD icon
553
Ironwood Pharmaceuticals
IRWD
$614M
$3.26M 0.03%
735,436
+72,502
+11% +$294K
FLNC icon
554
Fluence Energy
FLNC
$1.79B
$3.26M 0.03%
+205,000
New +$4.01M
HOV icon
555
Hovnanian Enterprises
HOV
$758M
$3.24M 0.03%
24,200
BFAM icon
556
Bright Horizons
BFAM
$4.1B
$3.16M 0.03%
28,506
+4,300
+18% +$517K
UNF icon
557
Unifirst Corp
UNF
$5.31B
$3.15M 0.03%
18,430
ITCI
558
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.13M 0.03%
37,500
AXSM icon
559
Axsome Therapeutics
AXSM
$12.1B
$3.13M 0.03%
37,000
+14,500
+64% +$1.33M
NN icon
560
NextNav
NN
$1.83B
$3.08M 0.03%
197,894
-208,000
-51% -$2.77M
DFIN icon
561
Donnelley Financial Solutions
DFIN
$1.17B
$3.07M 0.03%
48,969
-47,659
-49% -$2.97M
CTKB icon
562
Cytek Biosciences
CTKB
$557M
$3.06M 0.03%
470,819
+289,425
+160% +$1.72M
FCX icon
563
Freeport-McMoran
FCX
$91.2B
$3.05M 0.03%
80,000
SLAB icon
564
Silicon Laboratories
SLAB
$7.15B
$3.04M 0.03%
24,500
VKTX icon
565
Viking Therapeutics
VKTX
$3.86B
$3.03M 0.03%
75,261
+61,927
+464% +$3.53M
TELA icon
566
TELA Bio
TELA
$31.8M
$3.02M 0.03%
+1,000,064
New +$2.81M
J icon
567
Jacobs Solutions
J
$15.7B
$3.01M 0.03%
22,725
LRN icon
568
Stride
LRN
$3.53B
$2.98M 0.03%
28,678
-90
-0.3% -$8.56K
BWMN icon
569
Bowman Consulting
BWMN
$453M
$2.92M 0.03%
117,140
-53,565
-31% -$1.3M
RDN icon
570
Radian Group
RDN
$5.16B
$2.91M 0.03%
91,603
+7,914
+9% +$269K
ZUMZ icon
571
Zumiez
ZUMZ
$334M
$2.89M 0.03%
150,837
-27,163
-15% -$580K
TXRH icon
572
Texas Roadhouse
TXRH
$13.7B
$2.89M 0.03%
16,000
AEHR icon
573
Aehr Test Systems
AEHR
$2.51B
$2.86M 0.03%
171,765
INGN icon
574
Inogen
INGN
$174M
$2.85M 0.03%
311,199
+259,308
+500% +$2.43M
PRO
575
DELISTED
PROS Holdings
PRO
$2.81M 0.03%
128,164
+81,500
+175% +$1.75M

Similar funds

Royce & Associates's Q4 2024 Portfolio in Review

As of Q4 2024, Royce & Associates held 920 positions worth $10.8B, down 2% from $11B the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.

Royce & Associates's Q4 2024 filing shows 57 new, 332 increased, 337 reduced and 91 closed positions. Its largest new stake was AMERISAFE: 305,361 shares worth $15.7M. The largest sale was Ziff Davis, an estimated $33.8M.

By sector, the portfolio is most concentrated in Industrials at 25% of assets, down from 27% a quarter earlier, followed by Technology and Financials.

  • Royce & Associates's largest Q4 2024 buy was AMERISAFE: 305,361 shares worth $15.7M.
  • Royce & Associates added most to LCI Industries in Q4 2024, an estimated $19.9M increase.
  • Royce & Associates's biggest Q4 2024 reduction was Ziff Davis, cutting an estimated $33.8M.
  • Royce & Associates fully exited Carter's in Q4 2024, selling an estimated $13.1M.
  • Royce & Associates's ten largest holdings make up 9.2% of its $10.8B portfolio in Q4 2024.
  • Royce & Associates opened 57 new positions and closed 91 in Q4 2024.
  • Royce & Associates's portfolio value fell 2% quarter-over-quarter to $10.8B.

Based on Royce & Associates's 13F filing for Q4 2024, filed 10 Feb 2025.